AtriCure Inc. (ATRC) is EAM Investors LLC’s 8th Largest Position
EAM Investors LLC lessened its position in AtriCure Inc. (NASDAQ:ATRC) by 5.1% in the 3rd quarter, Holdings Channel reports. The fund owned 147,410 shares of the medical device company’s stock after selling 8,001 shares during the period. AtriCure comprises 0.8% of EAM Investors LLC’s investment portfolio, making the stock its 8th largest holding. EAM Investors LLC’s holdings in AtriCure were worth $5,164,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of ATRC. JPMorgan Chase & Co. boosted its position in AtriCure by 105.1% in the 1st quarter. JPMorgan Chase & Co. now owns 14,208 shares of the medical device company’s stock valued at $292,000 after buying an additional 7,281 shares during the last quarter. Bank of Montreal Can bought a new position in AtriCure in the 2nd quarter valued at $1,059,000. TD Asset Management Inc. boosted its position in AtriCure by 87.7% in the 2nd quarter. TD Asset Management Inc. now owns 64,600 shares of the medical device company’s stock valued at $1,747,000 after buying an additional 30,184 shares during the last quarter. Sei Investments Co. boosted its position in AtriCure by 958.4% in the 2nd quarter. Sei Investments Co. now owns 42,960 shares of the medical device company’s stock valued at $1,162,000 after buying an additional 38,901 shares during the last quarter. Finally, EAM Global Investors LLC bought a new position in AtriCure in the 2nd quarter valued at $1,449,000. 80.20% of the stock is currently owned by institutional investors.
NASDAQ:ATRC opened at $32.22 on Friday. AtriCure Inc. has a 12-month low of $14.88 and a 12-month high of $36.49. The company has a current ratio of 2.62, a quick ratio of 1.96 and a debt-to-equity ratio of 0.31.
A number of brokerages have commented on ATRC. Zacks Investment Research lowered AtriCure from a “hold” rating to a “sell” rating in a research report on Monday, August 6th. ValuEngine upgraded AtriCure from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 3rd. Canaccord Genuity raised their price target on AtriCure from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, October 9th. Needham & Company LLC restated a “buy” rating and issued a $39.00 price target on shares of AtriCure in a research report on Friday, October 12th. Finally, Stifel Nicolaus raised their price target on AtriCure from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Thursday, August 2nd. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $35.80.
AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.
Further Reading: Earnings Reports
Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure Inc. (NASDAQ:ATRC).
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.